Top-News
Biotechnologie Dänemark

Genmab News

Aktie
WKN:  565131 ISIN:  DK0010272202 US-Symbol:  GNMSF
263,10 €
+2,50 €
+0,96%
02.05.24 14:27:54
Handeln Depot/Watchlist
Aktienanzahl *
65,39 Mio.
Marktkapitalisierung *
16,94 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 06.11.2023

Ad-hocs

26.03.14 - DGAP
Ad hoc: Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen
Genmab A/S 26.03.2014 23:46 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
18.10.13 - DGAP
Ad hoc: GSK and Genmab Announce Submission to US Regulatory Authorities for Arzerra(r) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Genmab A/S 18.10.2013 22:18 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
10.10.13 - DGAP
Ad hoc: Genmab Announces Positive Top-Line Phase II Results of Ofatumumab in Multiple Sclerosis
Genmab A/S 10.10.2013 19:47 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
04.10.13 - DGAP
Ad hoc: GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(r) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Genmab A/S 04.10.2013 09:58 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
13.09.13 - DGAP
Ad hoc: FDA Grants GSK and Genmab's Arzerra(r) (Ofatumumab) Breakthrough Therapy Designation for Previously Untreated Chronic Lymphocytic Leukemia
Genmab A/S 13.09.2013 22:21 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
10.09.13 - DGAP
Ad hoc: Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma
Genmab A/S 10.09.2013 07:21 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
26.08.13 - DGAP
Ad hoc: Genmab Reaches Milestone in DuoBody Platform Collaboration with Janssen
Genmab A/S 26.08.2013 09:10 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
24.07.13 - DGAP
Ad hoc: Arzerra(r) Second Quarter 2013 Net Sales Figures
Genmab A/S 24.07.2013 13:04 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
18.07.13 - DGAP
Ad hoc: Genmab Files IND for HuMax-TF-ADC
Genmab A/S 18.07.2013 16:30 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
16.07.13 - DGAP
Ad hoc: Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Genmab A/S 15.07.2013 23:56 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
04.07.13 - DGAP
Ad hoc: Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder
Genmab A/S 04.07.2013 07:42 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
11.06.13 - DGAP
Ad hoc: Teprotumumab Restarts Clinical Development in New Indication
Genmab A/S 11.06.2013 21:54 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this ...
31.05.13 - DGAP
Ad hoc: Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program
Genmab A/S 31.05.2013 15:13 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...
29.05.13 - DGAP
Ad hoc: GSK and Genmab Announce Positive Top-line Results from Pivotal Study of ARZERRA(r) (ofatumumab) Combined with Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia
Genmab A/S 29.05.2013 19:05 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...
17.05.13 - DGAP
Ad hoc: Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Genmab A/S 17.05.2013 12:34 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...
01.05.13 - DGAP
Ad hoc: Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Bendamustine in Untreated and Relapsed Chronic Lymphocytic Leukemia
Genmab A/S 01.05.2013 18:44 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...
01.05.13 - DGAP
Ad hoc: Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration
Genmab A/S 01.05.2013 17:42 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...
24.04.13 - DGAP
Ad hoc: Arzerra First Quarter 2013 Net Sales Figures
Genmab A/S 24.04.2013 13:02 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...
17.04.13 - DGAP
Ad hoc: Passing of Genmab A/S' Annual General Meeting
Genmab A/S 17.04.2013 16:00 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...
16.04.13 - DGAP
Ad hoc: Genmab Announces Final US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Genmab A/S 16.04.2013 20:11 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this ...

Newssuche

Videos

newspaper
30.04.24 +18,03%
Technical Trading: Sojabohnen Long bis Juli
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »